Abnormalities in catecholamines and the pathophysiology of bipolar disorder

Bipolar Disorders: Basic Mechanisms and Therapeutic Implications, Second Edition

Volumn , Issue , 2007, Pages 33-65

  Garakani, Amir ^a   Charney, Dennis S ^a   Anand, Amit ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925598171     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (224)

1. Antelman SM, Caggiula AR, Kucinski BJ, et al. The effects of lithium on a potential cycling model of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22:495-510.
2. Moore H, Todd CL, Grace AA. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci 1998; 18:5068-5077.
3. Hyman SE, Nestler E. Molecular Basis of Psychiatry. Washington, DC: American Psychiatric Press, Inc., 1993.
4. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. New York: Oxford University Press, 1996.
5. Self DW, Barnhart WJ, Lehman DA, et al. Opposite modulation of cocaine-seeking behavior by Dl- and D2-like dopamine receptor agonists. Science 1996; 271:1586-1589.
6. Schultz W. Dopamine neurons and their roles in reward mechanisms. Curr Opin Neurobiol 1997; 7:191-197.
7. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press, 1995:921-931.
8. Carroll BJ. Psychopathology and neurobiology of manic-depressive disorders. In: Carroll BJ, Barret JE, eds. Psychopathology and the Brain. New York: Raven Press, 1991:265-285.
9. Depue RA, Iacono W. Neurobehavioral aspects of bipolar disorder. Annu Rev Psychol 1989; 40:457-492.
10. Redmond DE. Studies of the Nucleus Locus Coeruleus in Monkeys and Hypothesis for Neuropsychopharmacology. New York: Raven Press, 1987.
11. Woodward DJ, Moises HC, Waterhouse BD, et al. Modulating actions of norepinephrine in the central nervous system. Federation Proc 1979; 38:2109-2116.
12. Charney DS, Southwick SM, Delgado PL, et al. Current Status of the Receptor Sensitivity Hypothesis of Antidepressant Action: Implications for the Treatment of Severe Depression. Basel: Marcel Dekker, 1990.
13. Bylund DB. Subtypes of c2-adrenoreceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 1988; 9:356-361.
14. Mongeau R, Blier P, de Montigny C. In vivo electrophysological evidence for tonic activation by endogenous noradrenaline of a2-adrenoreceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schrniedberg’s Arch Pharmacol 1993; 347:266-272.
15. Sara SJ. Learning by neurones: role of attention, reinforcement and behaviour. Comp Rend Acad Sci 1998; 321:193-198.
16. Grenhoff J, Nisell M, Ferre S, et al. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm 1993; 93:11-25.
17. James W. The Principles of Psychology Vols. 1 and 2. New York: Dover Publications, 1890 and 1950.
18. Selye H. Selye’s Guide to Stress Research. Vol. 1. New York: Van Nostrand Reinhold, 1980.
19. MacLean PD. Some psychiatric implications of physiological studies on frontotemporal portion of limbic system (visceral brain). Electroencephaologr Clin Neurophysiol 1952; 4:407-418.
20. Papez JW. A proposed mechanism of emotion. Arch Neurol Psychiatry 1937; 38: 725-743.
21. Damasio AR. Descarte’s Error: Emotion, Reason, and the Human Brain. New York: Grosset/Putnam, 1994.
22. Graybiel AM. The basal ganglia and cognitive pattern generators [see comments]. Schizophrenia Bull 1997; 23:459-469.
23. Nauta WJH. Reciprocal links of the corpus striatum with the cerebral cortex: a common substrate for movement and thought. In: Mueller E, ed. Neurology and Psychiatry: A Meeting of Minds. Basel: Karger, 1989:43-63.
24. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing [see comments], Trends Neurosci 1990; 13:266-271.
25. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Progr Brain Res 1990; 85:119-146.
26. Cummings JL. Anatomic and behavioral aspects of frontal-subcortical circuits. Ann Acad Sci 1995; 769:1-13.
27. Damasio AR. Towards a neuropathology of emotion and mood. Nature 1997; 386:769-770.
28. Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386:824-827.
29. Swerdlow NR, Koob GP. Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci 1987; 10:197-245.
30. Anand A, Li Y, Wang Y, et al. Activity and connectivity of mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 2005; 15:1079-1088.
31. McCormick D. Membrane properties and neurotransmitter action. In: Shepherd GM, ed. Synaptic Organization of the Brain. New York: Oxford University Press, 1998:37-78.
32. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13:244-254.
33. Shepherd GM. Neurobiology. New York: Oxford University Press, 1994.
34. Lopez HS, Brown AM. Neuromodulation. Curr Opin Neurobiol 1992; 2:317-322.
35. Graybiel AM. The basal ganglia and the initiation of movement. Rev Neurol 1990; 146:570-574.
36. Dunwidde TV, Taylor M, Heginbotham LP, et al. Long-term increases in excitability in the CAI region of the rat hippocampus induced by beta-adrenergic stimulation: possible mediation by cAMP. J Neurosci 1992; 12:506-507.
37. Berthier ML, Kulisevsky J, Gironell MD, et al. Poststroke bipolar affective disorder. J Neuropsychiatry Clin Neurosci 1996; 8:160-167.
38. Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobiol 1996; 13:33-60.
39. Wikinson DM, Halpern LM. The role of biogenic amines in amygdalar kindling. I. Local amygdalar after discharge. J Pharmacol Exp Ther 1979; 211:151-158.
40. Wickens JR, Begg Al. Dopamine reverses the depression of rat corticostriatal synapses which normally follows high-frequency stimulation of cortex in vitro. Neuroscience 1996; 70:1-5.
41. Schildkraut J. The catecholamine hypothesis of affective disorder: a review of supporting evidence. Am J Psychiatry 1965; 122:509-522.
42. Bunney WEJ, Davis JM. Norepinephrine in depressive reactions. Arch Gen Psychiatry 1965; 13:483-494.
43. Bunney WE, Garland BL. A second generation catecholamine hypothesis. Pharmacopsychiatry 1982; 15:111-115.
44. Coppen AJ. Depressed states and indolealkylamines. Adv Pharmacol 1968; 6 (Pt B):283-91.
45. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; 1(7586):132-136.
46. Prange AJ Jr, Wilson IC, Lynn CW, et al. L-tryptophan in mania: Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974; 30(1):56-62.
47. Kopin IJ, Gordon EK, Jimerson, DC, et al. Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 1983; 219:73-75.
48. Charney DS, Heninger GR, Sternberg DE, et al. Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 1981; 38:1160-1180.
49. Schatzberg AF, Orsulak PJ, Rosenbaum AU, et al. Toward a biochemical classification of depressive disorders. V. Heterogeneity of unipolar depressions. Am J Psychiatry 1982; 139:471-475.
50. Koslow SH, Maas Jam, Bowden CL, et al. CSF and urinary biogenic amines and metabolites in depression and mania. Arch Gen Psychiatry 1983; 40:999-1010.
51. Agren H. Depressive symptom patterns and urinary MHPG excretion. Psychiatry Res 1982; 6:185-196.
52. Schatzberg AF, Schildkraut AF. Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995:911-920.
53. Schatzberg AF, Samson JA, Bloomingdale KL, et al. Toward a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites, and D-type scores in sub-groups of depressive disorders. Arch Gen Psychiatry 1989; 46:260-268.
54. Goodwin FK, Jamison KR. Manic Depressive Illness. New York: Oxford University Press, 1990.
55. Depue RA, Arbisi F, Krauss S, et al. Seasonal independence of low prolactin concentration and highspontaneous eye blink rates in unipolar and bipolar II seasonal affective disorder. Am J Psychiatry 1990; 47:356-364.
56. Engelman K, Horowiz D, Jequier E. Biochemical and pharmacological effects of alphamethyltyrosine in man. J Clin Invest 1968; 47:577-594.
57. Brodie HKH, Murphy DL, Goodwin FK, et al. Catecholamines and mania: the effect of alpha-methyl-paratyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther 1971; 12:218-224.
58. Berman RM, Narasimhan M, Miller HL, et al. Transient depressive relapse induced by catecholamine depletion potential phenotypic vulnerability marker? Arch Gen Psychiatry 1999; 56:395-403.
59. Anand A, Darnell A, Miller HL, et al. Effect of catecholamine depletion on lithiuminduced long-term remission of bipolar disorder. Biol Psychiatry 1999; 45:972-978.
60. Anand A, Verhoeff P, Seneca N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000; 157(7):1108-1114.
61. Gerner RM, Post RM, Bunney WE. A dopaminergic mechanism in mania. Am J Psychiatry 1976; 113:1177-1180.
62. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23(3):285-300.
63. Jacobson D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model of mania. Psychol Med 1986; 16:323-329.
64. Nurnberger JIJ, Gershon ES, Simmons S, et al. Behavioral, biochemical and neuroendocrine responses to amphetamine in normal twins and “well-state” bipolar patients. Psychoneuroendocrinology 1982; 7:163-176.
65. McTavish SF, McPherson MH, Harmer CJ, et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 2001; 179:356-360.
66. Silverstone T. Response to bromocriptine distinguishes bipolar from unipolar depression [letter]. Lancet 1984; 1:903-904.
67. Post RM, Lake CR, Jimerson DC, et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pre-treatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35:609-615.
68. Price LH, Charney DS, Heninger GR. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 1984; 141:1267-1268.
69. Machado-Vieira R, Viale CI, Kapczinski F. Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol. Can J Psychiatry 2001; 46(5):454-455.
70. Ogawa N, Ueki H. Secondary mania caused by caffeine. Gen Hosp Psychiatry 2003; 25(2):138-139.
71. Anand A, Charney DS. Catecholamines in depression. In: van Praag RM, Honig A, eds. Depression: Neurobiological, Psychopathological and Therapeutic Advances. London, UK: John Wiley & Sons Ltd., 1997:147-178.
72. Meltzer H Y, Kolakowska T, Fang VS, et al. Growth hormone and prolactin response to apomorphine in schizophrenia and major affective disorders. Relation to duration of illness and affective symptoms. Arch Gen Psychiatry 1984; 41:512-519.
73. Hirschowitz J, Zemlan FP, Hitzemann RJ, et al. Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems. Biol Psychiatry 1986; 21:445-454.
74. McPherson H, Walsh A, Silverstone T. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. J Affect Disord 2003; 76(1-3):121-125.
75. Linkowski P, Brauman H, Mendlewicz J. Prolactin and growth hormone response to levodopa in affective illness. Neuropsychobiology 1983; 9:108-112.
76. Matussek N. Catecholamines and mood: neuroendocrine aspects. Curr Top Neuroendocrinol 1988; 8:145-182.
77. Charney DS, Heninger GR, Sternberg DE, et al. Adrenergic receptor sensitivity in depression: effects of clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry 1982; 39:290-294.
78. Ansseau M, von Erenckell R, Cerfontaine JL, et al. Neuroendocrine evaluation of catecholaminergic neurotransmission in mania. Psychiatry Res 1987; 22:193-206.
79. Ansseau M, Cerfontaine R, et al. Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Br J Psychiatry 1988; 153:65-171.
80. Langer G, Heinze O, Reim B, et al. Growth hormone response to d-amphetamine in normal controls and depressive patients. Neurosci Lett 1975; 1:185-189.
81. Anand A, Charney DS, McDougle CJ, et al. Neuroendocrine and behavioral responses to m-chlorophenylpiperazine (MCPP) in depression. Am J Psychiatry 1994; 151:1626-1630.
82. Rubinow DR, Gold PW, Post RM, et al. CSF Somatostatin in affective illness. Arch Gen Psychiatry 1983; 40:409-412.
83. Waldmeier PC. Is there a common denominator for the anti-manic effects of lithium and anticonvulsants? Pharmacopsychiatry 1987; 20:37-47.
84. Cervo L, Samanin R. Repeated treatment with imipramine and amitryptline reduces the immobility of rats in the swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J Pharmac Pharmacol 1988; 40:155-156.
85. Özerdem A, Schmidt ME, Manji HK, et al. Chronic lithium administration enhances noradrenergic responses to intravenous administration of the alpha2 antagonist idazoxan in healthy volunteers. J Clin Psychopharmacol 2004; 24(2):150-154.
86. Swann AC, Koslow SH, Katz MM, et al. Lithium carbonate treatment of mania. Arch Gen Psychiatry 1987; 44:345-354.
87. Giannini AJ, Pascarazi GA, Loiselle RH, et al. Comparison of clonidine and lithium in the treatment of mania. Am J Psychiatry 1986; 143:1608-1609.
88. Hardy M, Lecrubier 17, Widlocher D. Efficacy of clonidine in 24 patients with acute mania. Am J Psychiatry 1986; 143:1450-1453.
89. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited [see comments]. Am J Psychiatry 1995; 152:1130-1138.
90. Kjellman BF, Karlberg BE, Morel LE. Serum dopamine-beta-hydroxylase activity in patients with major depressive disorders. Acta Psychiatr Scand 1986; 73:266-270.
91. Levitt N, Dunner DL, Mendlewicz J, et al. Plasma dopamine hydroxylase activity in bipolar disorder. Psychopharmacologia 1976; 46:205-210.
92. Rihmer Z, Bagdy G, Arato M. Serum dopamine-beta-hydroxylase activity and family history of patients with bipolar manic-depressive illness. Acta Psychiatr Scand 1983; 68:140-141.
93. Strandman E, Wetterberg L, Perris C, et al. Serum dopamine-beta-hydroxylase in affective disorders. Neuropsychobiology 1978; 4:248-255.
94. Puzynski S, Rode A, Zaluska M. Studies on biogenic amine metabolizing enzymes (DBH, COMT, MAO) and pathogenesis of affective illness. I. Plasma dopamine-betahydroxylase activity in endogenous depression. Acta Psychiatr Scand 1983; 67:89-95.
95. Ikeda Y, Ijima M, Nomura S. Serum dopamine-beta-hydroxylase in manicdepressive psychosis. Br J Psychiatry 1982; 140:209-210.
96. Murphy DL, Coursey RD, Haenel T, et al. Platelet monoamine oxidase as a biological marker in the affective disorders and alcoholism. In: Usdin E, Hanin 1, eds. Biological Markers in Psychiatry and Neurology. Oxford: Pergamon Press, 1982: 123-134.
97. Dunner DL, Levitt M, Kumbaraci T, et al. Erythrocyte catechol-O-methyltransferase activity in primary affective disorder. Biol Psychiatry 1977; 12:237-244.
98. Maj M, Grazia A, Arena F, et al. Plasma cortisol, catecholamine and cyclic AMP levels, response to dexamethasone suppression test and platelet MAO activity in manicdepressive patients. Neuropsychobiology 1984; 11:168-173.
99. Papolos DF, Veit S, Faedda GL, et al. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele. Mol Psychiatry 1998; 3(4):346-349.
100. Graf WD, Unis AS, Yates CM, et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 2001; 57(3):410-416.
101. Siever LJ, Uhde TW, Insel TR, et al. Growth hormone response to clonidine unchanged by chronic clorgyline treatment. Psychiatry Res 1982; 7:139-144.
102. Garcia-Sevilla JA, Padro D, Giralt T, et al. a2-Adrenoreceptor mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression: effect of long-term cyclic antidepressant drug treatment. Arch Gen Psychiatry 1990; 47:125-132.
103. Piletz JE, Schubert DSP, Halaris A. Evaluation of studies on platelet a2 adrenoreceptors in depressive illness. Life Sci 1986; 39:1589-1616.
104. Kindler SL. Norepinephrine and depression: a reappraisal. In: Pohl RG, ed. The Biologic Basis of Psychiatric Treatment. Progress in Basic and Clinical Pharmacology. Vol. 3. Basel: Karger, 1990:120-141.
105. Buckholtz NS, Davies AO, Rudorfer MV, et al. Lymphocyte beta adrenergic receptor function versus catecholamines in depression. Biol Psychiatry 1988; 24:451-457.
106. Wright AF, Crichton DN, Loudon JB, et al. Beta-adrenoreceptor binding defects in cell lines from families with manic-depressive disorder. Ann Hum Genet 1984; 48:201-204.
107. Berrettini WH, Bardakjian J, Barnett AL Jr, et al Beta-adrenoceptor function in human adult skin fibroblasts: a study of manic-depressive illness. Ciba Foundation Symp 1986; 123:30-41.
108. Berrettini WH, Cappellari CB, Numberger JI Jr, et al. Beta-adrenergic receptors on lymphoblasts. A study of manic-depressive illness. Neuropsychobiology 1987; 17:15-18.
109. Manji HK, Lenox RH. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994; 16:11-28.
110. Baraban JM, Worley PF, Snyder SH. Second messenger and psychoactive drug action: focus on the phosphoinositide system and lithium. Arch J Psychiatry 1989; 146:1251-1260.
111. Berridge MJ. The Albert Lasker Medical Awards. Inositol trisphosphate, calcium, lithium, and cell signaling. JAMA 1989; 262:1834-1841.
112. Lenox RH, McNamara RK, Papke RL, et al. Neurobiology of lithium: an update. J Clin Psychiatry 1998; 59(suppl 6):37-47.
113. Manji HK, Bebchuk JM, Moore GJ, et al. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 1999; 60(suppl 2):27-39, discussion 40-41, 113-116.
114. Chen G, Huang LD, Jiang YM, et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72:1327-1330.
115. Freidman E, Hoau YW, Levinson D, et al. Altered platelet protein kinase C activity in bipolar affective disorder-manic episode. Biol Psychiatry 1993; 33:520-525.
116. Kaya N, Resmi H, Özerdem A, et al. Increased inositol-monophosphatase activity by lithium treatment in bipolar patients. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(3):521-527.
117. Young LT, Li PP, Kish SJ, et al. Postmortem cerebral cortex Gs alpha-subunit levels are elevated in bipolar affective disorder. Brain Res 1991; 553:323-326.
118. Young LT, Li PP, Kish SJ, et al. Cerebral cortex Gs alpha protein levels and forskolinstimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993; 61:890-898.
119. Young LT, Warsh JJ, Kish SJ, et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 1994; 35:121-127.
120. Young LT, Li PP, Kish SJ, et al. Cerebral cortex beta-adrenoceptor binding in bipolar affective disorder. J Affect Discord 1994; 30:89-92.
121. Rahman S, Li PP, Young LT, et al. Reduced 3[M]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 1997; 68:297-304.
122. Friedman E, Wang HY. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 1996; 67(3):1145-1152.
123. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996; 40:568-575.
124. Dean B, Scarr E, McLeod M. Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder. Brain Res Mol 2005; 138(2):145-155.
125. Altschuler LL, Conrad A, Hauser P, et al. T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am J Psychiatry 1995; 152:1139-1144.
126. Aylward EH, Roberts-Twille JV, Barta PE, et al. Basal ganglia volumes and white matter intensities in patients with bipolar disorder. Am J Psychiatry 1994; 151:687-693.
127. Strakowski SM, Wilson DR, Tohen M, et al. Structural brain abnormalities in firstepisode mania. Biol Psychiatry 1993; 33:204-206.
128. Strakowski SM, DelBello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in firstversus multiple-episode bipolar disorder. Am J Psychiatry 2002; 159:1841-1847.
129. DelBello MP, Strakowski SM, Zimmerman ME, et al. MRI analysis of the cerebellum in bipolar disorder: a pilot study. Neuropsychopharmacology 1999; 21(1):63-68.
130. Mills NP, Delbello MP, Adler CM, et al. MRI analysis of cerebellar vermal abnormalities in bipolar disorder. Am J Psychiatry 2005; 162(8):1530-1532.
131. Soares JC, Mann JJ. The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiatry 1997; 41:86-106.
132. Altshuler LL, Bartzokis G, Grieder T, et al. An MRI study of temporal lobe structures in men with bipolar disorder and schizophrenia. Biol Psychiatry 2000; 48:147-162.
133. Brambilla P, Harenski K, Nicoletti M, et al. MRI investigation of temporal lobe structures in bipolar patients. J Psychiatr Res 2003; 37:287-295.
134. Kemmerer M, Nasarallah HA, Sharma S, et al. Increased hippocampal volume in bipolar disorder [abstract]. Biol Psychiatry 1994; 35:626.
135. Krishnan KR, Doraiswamy PM, Figiel GS, et al. Hippocampal abnormalities in depression. J Neuropsychiatry Clin Neurosci 1991; 3:387-391.
136. Krishnan KR, McDonald WM, Escalona PR, et al. Magnetic resonance of the caudate nuclei in depression. Preliminary observations. Arch Gen Psychiatry 1992; 49:553-557.
137. Hirayasu Y, Shenton ME, Salisbury DF, et al. Subgenual cingulate cortex volume in first-episode psychosis. Am J Psychiatry 1999; 156:1091-1093.
138. Al-Mousawi AH, Evans N, Ebmeier KP, et al. Limbic dysfunction in schizophrenia and mania. A study using 18F-labelled fluorodeoxyglucose and positron emission tomography. Br J Psychiatry 1996; 169:509-516.
139. Gyulai L, Alavi A, Broieh K, et al. I-123 iofetamine single-photon computed emission tomography in rapid cycling bipolar disorder: a clinical study. Biol Psychiatry 1997; 41:152-161.
140. Migliorelli R, Starkstein SE, Teson A, et al. SPECT findings in patients with primary mania. J Neuropsychiatry Clin Neurosci 1993; 5:379-383.
141. O’Connell RA, Van Heertum RL, Luck D, et al. Single-photon emission computed tomography of the brain in acute mania and schizophrenia. J Neuroimaging 1995; 5:101-104.
142. Pearlson GD, Wong DF, Tune LE, et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995; 52:471-477.
143. Wong WF, Pearlson GD, Tune LE, et al. Quantification of neuroreceptors in the living human brain. IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997; 17:331-342.
144. Gjedde A, Wong DF. Quantification of neuroreceptors in living human brain. V. Endogenous neurotransmitter inhibition of haloperidol binding in psychosis. J Cereb Blood Flow Metab 2001; 21(8):982-994.
145. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002; 159(5):768-774.
146. D’haenen H, Bossuyt A. Dopamine D2 receptors in the brain measured with SPECT. Biol Psychiatry 1994; 35:128-132.
147. Anand A, Verhoeff P, Seneca N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000; 157(7):1108-1114.
148. Yatham LN, Liddle PF, Lam RW, et al. PETstudy of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry 2002; 159(10):1718-1723.
149. Perez de Castro I, Santos J, Torres P, et al. A weak association between TH and DRD2 genes and bipolar. J Med Genet 1995; 32:131-134.
150. Smyth C, Kalsi G, Brynjolfsson J, et al. Further tests for linkage of bipolar affective. Am J Psychiatry 1996; 153:271-274.
151. Kawada Y, Hattori M, Fukuda R, et al. No evidence of linkage or association between tyrosine hydroxylase gene. J Affect Dis 1995; 34:89-94.
152. Souery D, Lipp O, Mahieu B, et al. Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. Am J Med Genet 1996; 67:551-555.
153. Turecki G, Rouleau GA, Mari J, et al. Lack of association between bipolar disorder and tyrosine hydroxylase: a meta-analysis. Am J Med Genet 1997; 74(4):348-352.
154. Souery D, Lipp O, Rivelli SK, et al. Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: a multicenter association study. Am J Med Genet 1999; 88(5):527-532.
155. Kunugi H, Vallada HP, Hoda F, et al. No evidence for an association of affective disorders, Biol Psychiatry 1997; 42:282-285.
156. Mynett-Johnson LA, Murphy VE, Claffey E, et al. Preliminary evidence of an association between bipolar disorder in females and the catechol-O-methyltransferase gene. Psychiatr Genet 1998; 8(4):221-225.
157. Kirov G, Murphy KC, Arranz MJ, et al. Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 1998; 3(4):342-345.
158. Lim LC, Powell J, Sham P, et al. Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am J Med Genet 1995; 60(4):325-331.
159. Rubinsztein DC, Leggo J, Goodburn S, et al. Genetic association between monoamine oxidase A and bipolar disorder. Hum Mol Genet 1996; 5:779-782.
160. Parsian A, Todd RD. Genetic association between monoamine oxidase and bipolar disorder. Am J Med Genet 1997; 74(5):475-479.
161. Homer JP, Flodman PL, Spence MA. Bipolar disorder: dominant or recessive. Genetic Epidemiol 1997; 14:647-651.
162. Waldman ID, Robinson BF, Feigon SA. Linkage disequilibrium between the dopamine transporter gene (DAT1). Genet Epidemiol 1997; 14:699-704.
163. Heiden A, Schussler P, Itzlinger U, et al. Association studies of candidate genes in bipolar disorders. Neuropsychobiology 2000; (42 suppl 1):18-21.
164. Stober G, Jatzke S, Hells A, et al. Insertion/deletion variant (-141C Ins/Del) in the 5' regulatory region. J Neural Transm 1998; 105:101-109.
165. Leszczynska-Rodziewicz A, Czerski PM, Kapelski P, et al. A polymorphism of the norepinephrine transporter gene in bipolar disorder and schizophrenia: lack of association. Neuropsychobiology 2002; 45(4):182-185.
166. Horiuchi Y, Nakayama J, Ishiguro H, et al. Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders. Biol Psychiatry 2004; 55(1):40-45.
167. Massat I, Souery D, Del-Favero J, et al. Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Mol Psychiatry 2002; 7(2):201-207.
168. Otani K, Ujike H, Tanaka Y, et al. The GABA type A receptor alpha5 subunit gene is associated with bipolar I disorder. Neurosci Lett 2005; 381(1-2):108-113.
169. Massat I, Souery D, Del-Favero J, et al. Lack of association between GABRA3 and unipolar affective disorder: a multicentre study. Int J Neuropsychopharmacol 2001; 4(3):273-278.
170. Ambrosio AM, Kennedy JL, Macciardi F, et al. A linkage study between the GABAA beta2 and GABAA gamma2 subunit genes and major psychoses. CNS Spectr 2005; 10(1):57-61.
171. Ram A, Guedj F, Cravchik A, et al. No abnormality in the gene for the G protein stimulatory alpha subunit in. Arch Gen Psychiatry 1997; 54:44-48.
172. Garvey MJ, Noyes R Jr, Cook B, et al. Preliminary confirmation of the proposed link between reward-dependence traits and norepinephrine. Psychiatry Res 1996; 65:61-64.
173. Antelman SM, Caggiula AR. Norepinephrine-dopamine interactions and behavior. Science 1977; 195:646-653.
174. Archer T, Fredriksson A, Jonsson G, et al. Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology 1986; 88:141-146.
175. Tassin J. Norepinephrine-dopamine interactions in the pre-frontal cortex and the ventral tegmental area; relevance to mental diseases. Adv Pharmacol 1998; 42:712-716.
176. Soderpalm B, Andersson L, Carlsson M, et al. Serotonergic influence on the growth hormone response to clonidine in the rat. J Neural Transm 1987; 69:105-114.
177. Gillespie DD, Manier DH, Sanders-Bush E, et al. The serotonergic/noradrenergic link in brain. II. Role of serotonin in the regulation of beta adrenoreceptors in the low agonist affinity conformation. J Pharmacol Exp Ther 1988; 244:154-459.
178. Chiang C, Aston-Jones G. A 5-hydroxytryptamine-2 agonist augments GABA and excitatatory amino acid inputs to nor-adrenergic locus coeruleus neurons. Neuroscience 1993; 54:409-420.
179. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978; 179:641-668.
180. Gershon SC, Baldessarini R. Motor effects of serotonin in the central nervous system. Life Sci 1980; 27:1435-1451.
181. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 1994; 271:83-90.
182. Spoont MR. Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 1992; 112:330-350.
183. deMontigny C, Tan AT, Caille G. Short-term lithium enhances 5-HT neurotransmission in rats administered chronic anti-depressant treatments. Paper presented at the Society for Neuroscience Annual Meeting, Los Angeles, CA, Oct 18-23, 1981.
184. Gravel P, de Montigny C. Noradrenergic denervation prevents sensitization of rat forebrain neurons to serotonin by tricyclic antidepressant treatment. Synapse 1987; 1:233-239.
185. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia (see comments). Am J Psychiatry 1991; 148:1301-1308.
186. Paul IA, Trullas R, Skolnick P, et al. Down-regulation of cortical b-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology 1992; 106:285-287.
187. Kitamura Y, Zhao X-H, Takei M, et al. Effects of antidepressants on the glutamatergic system in mouse brain. Neurochem Int 1991; 19:247-253.
188. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia [see comments]. Arch Gen Psychiatry 1995; 52:998-1007.
189. Anand A, Charney DS, Cappiello A, et al. Lamotrigine reduces the psychotomimetic- but not the mood elevating-effects of ketamine in humans. Paper presented at the American College of Neuropharmacology Meeting, Hawaii, 1997.
190. Calabrese JR, Rapport DJ, Shelton MD, et al. Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 1998; 38:185-191.
191. Grace AA, Moore H, O’Donnell P. The modulation of corticoaccumbens transmission by limbic afferents and dopamine: a model for the pathophysiology of schizophrenia. Adv Pharmacol 1998; 42:721-724.
192. Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004; 61(5):450-458.
193. Friedman SD, Dager SR, Parow A, et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry 2004; 56(5):340-348.
194. Shiah S-I, Yatham LN. GABA function in mood disorders; an update and critical review. Life Sci 1998; 63:1289-1303.
195. Valentino RJ, Curtis AL. Antidepressant interactions with corticotropin-releasing factor in the noradrenergic nucleus locus coeruleus. Psychopharmacol Bull 1991; 27:263-269.
196. Swann AC, Petty F, Bowden CL, et al. Mania: gender, transmitter function, and response to treatment. Psychiatry Res 1999; 88(1):55-61.
197. Nemeroff CB, Owens MJ, Bissette G, et al. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Science 1984; 226:1342-1344.
198. Veith RC, Lewis N, Langohr JI, et al. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 1993; 46:1-8.
199. Heilig M, Widerlov B. Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand 1990; 82:95-114.
200. Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 1991; 59:73-80.
201. Rubinow DR, Davis CL, Post RM. Somatostatin in neuropsychiatric disorders. Prog Neuropsychopharrnacol Biol Psychiatry 1988; 12:S137-S155.
202. Gheorvassaki EG, Thermos K, Liapakis G, et al. Effects of acute and chronic desipramine treatment on somatostatin receptors in brain. Psychopharrnacology 1992; 108:363-366.
203. Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982; 238:298-302.
204. Berrettini WH, Nurnberger JI Jr, Zerbe RL, et al. CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 1987; 150:208-212.
205. Janowsky DS, Yousef MK, Davis JM, et al. Parasympathetic suppression of manic symptoms by physostigmine. Ach Gen Psychiatry 1973; 28:542-547.
206. Belmaker RH, Zohar J, Levy A. Unidirectionality of lithium stabilization of adrenergic and cholinergic receptors. In: Emric H, Aldenhoff JB, Lux HD, eds. Basic Mechanisms in the Action of Lithium. Amsterdam: Excerpta Medica, 1982:146-153.
207. Whybrow PC, Prange AJ. A hypothesis of thyroid-catecholamine-receptor interaction. Arch Gen Psychiatry 1981; 38:106-113.
208. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am Psychiatry 1996; 153:151-162.
209. Wachtel H. Dysbalance of neuronal second messenger function in the etiology of affective disorders: apathophysiological concept hypothesizing defects beyond first messenger receptors. Neurotransm 1989; 75:21-29.
210. Lachman HM, Papolos DF. Abnormal signal transduction: a hypothetical model for bipolar affective disorder. Life Sci 1989; 45:1413-1426.
211. Lachman HM, Papolos DF. A molecular model for bipolar affective disorder. Med Hypoth 1995; 45:255-264.
212. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539-7547.
213. Siuciak JA, Anthony Altar CA, Wiegand SJ, et al. Antinociceptive effect of brain derived neurtrophic factors and neurotrophin-3. Brain Res 1994; 633:326-330.
214. Siuciak JA, Lewis D, Wiegand SJ, et al. Brain derived neurotrophic factor (BDNF) produces an anti-depressant like effect in two animal models of depression. Paper presented at the Society of Neuroscience Annual Meeting, Miami Beach, FL, Nov 13-18, 1994.
215. Arenas E, Persson H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 1994; 367:368-371.
216. Gash DM, Zhang Z, Gerhardt G. Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 1998; 44(3 suppl 1):S121-S125.
217. Bunney WE, Wu JC, Gillin C, et al. Clock genes: circadian abnormalities and therapeutic strategies in depression. Paper presented at the American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 1998.
218. Hastings M. The brain, circadian rhythms, and clock genes. Br Med J 1998; 317:1704-1707.
219. Lykouras L, Markianos M, Hatzimanolis J, et al. Biogenic amine metabolites in delusional depression and melancholia subtypes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(8):1261-1271.
220. Lykouras L, Markianos M, Hatzimanolis J, et al. Association of biogenic amine metabolites with symptomatology in delusional and non-delusional depression. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19(5):877-887.
221. Devanand DP, Bowers MBJ, Hoffman FJJ, et al. Elevated plasma homovanillic acid in depressed female patients with melancholia and psychosis. Psychiatry Res 1985; 42:923-926.
222. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980; 137:383-386.
223. Fibiger HC. The dopamine hypothesis of schizophrenia and mood disorders: contraindications and speculations. In: Winner P, Scheel-Kruger J, eds. The Mesolimbic Dopamine System: From Motivation to Action. London: John Wiley and Sons Ltd., 1991:615-636.
224. Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm 1993; 91:111-134.